January 31, 2015 7:20 AM ET

Pharmaceuticals

Company Overview of Romark Laboratories, L.C.

Company Overview

Romark Laboratories, L.C., a pharmaceutical company, discovers, develops, and commercializes small molecules for treating infectious diseases and cancers. It provides thiazolide and nitazoxanide antiviral drugs for treatment of chronic hepatitis C and influenza. The company was founded in 1993 and is headquartered in Tampa, Florida.

3000 Bayport Drive

Suite 200

Tampa, FL 33607

United States

Founded in 1993

Phone:

813-282-8544

Fax:

813-282-4910

Key Executives for Romark Laboratories, L.C.

Co-Founder
Chief Financial Officer
Chief Operating Officer and Executive Vice President
Compensation as of Fiscal Year 2014.

Romark Laboratories, L.C. Key Developments

Romark Laboratories L.C. to Open Plant in Puerto Rico

Romark Laboratories L.C. is building a $110 million plant in the U.S. territory. Construction will begin in January and that nearly 200 jobs will be created in three years. The plant is expected to manufacture and package Heartgard and Heartgard Plus products. The plant is expected to manufacture and package Heartgard and Heartgard Plus products.

Romark Laboratories, L.C. Wins $2 Million Federal Contract

Romark Laboratories, L.C. won a $2 million federal contract from the U.S. Department of Veterans Affairs' National Acquisition Center, Hines, Illinois, for medical equipment and supplies.

Romark Laboratories, L.C. and Lupin Limited Reach Strategic Agreement for Promotion and Distribution Of Alinia for Oral Suspension

Romark Laboratories, L.C. announced that it has entered into a strategic agreement with Lupin Limited and its subsidiaries (collectively Lupin) designed to expand promotion and distribution efforts related to its Alinia(R) (nitazoxanide) for Oral Suspension, 100 mg/5 mL. Under the agreement, Lupin acquired an exclusive license to promote and distribute Alinia for Oral Suspension in the United States. Lupin will promote the product using the pediatric-focused sales force of Lupin Pharmaceuticals. Alinia for Oral Suspension is approved by the U.S. Food and Drug Administration for treatment of diarrhea caused by Giardia lamblia or Cryptosporidium parvum in patients 12 months of age and older. The product has not been shown to be superior to placebo for the treatment of diarrhea caused by Cryptosporidium parvum in HIV-infected or immunodeficient patients. It is the only product approved for treatment of diarrhea caused by Cryptosporidium parvum and the only product approved in the United States for treating diarrhea caused by Giardia lamblia in children under 4 years of age. Cryptosporidium and Giardia are the two most common protozoan infections in the United States and worldwide. The U.S. Centers for Disease Control and Prevention (CDC) estimates that there are approximately 1.2 million cases of Giardia infection and 750,000 cases of Cryptosporidium infection annually in the United States, although most of these infections are undiagnosed. Romark will continue to promote and distribute Alinia (nitazoxanide) tablets, 500 mg, with its specialty sales force focused primarily on gastroenterologists and primary care physicians. The Company has recently expanded its specialty sales force from 16 to 30 representatives and plans to further expand to 50 representatives before the end of 2013.

Similar Private Companies By Industry

Company Name Region
Advenchen Laboratories, LLC United States
Aspen Park Pharmaceuticals, Inc. United States
ARIIX Holdings, LLC United States
NitroMed, Inc. United States
Otsuka Global Insurance Inc United States

Recent Private Companies Transactions

Type
Date
Target
Private Placement
May 27, 2014
--
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Romark Laboratories, L.C., please visit www.romark.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.